BWAY Stock Analysis: Buy, Sell, or Hold?
BWAY - Brainsway Ltd. American Depositary Shares
$14.27
-0.79 (-5.25%)
▼
5d:
-10.92%
30d:
+0.85%
90d:
+2.51%
WAIT
LOW Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 12, 2026
29d
Get Alerted When BWAY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called BWAY this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BWAY is down 10.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BWAY is down 10.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$26.29
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$16.32
12.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BWAY is currently trading at $14.27, which is considered slightly low relative to its 30-day fair value range of $14.21 to $15.17. From a valuation perspective, the stock is trading at a discount (Forward PE: 27.9) compared to its historical average (50.9). Remarkably, the market is currently pricing in an annual earnings decline of 18.2% over the next few years. This pessimistic expectation contrasts with the company's recent 200% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BWAY is in a downtrend. The price is currently testing key support at $14.33. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: BWAY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.50 (+16.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BWAY is in a downtrend. The price is currently testing key support at $14.33. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: BWAY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.50 (+16.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$14.21 -
$15.17
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.2%)
- BULLISH: Trading below Wall St target ($17.50)
- WARNING: Recommendation downgraded due to -10.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$14.21 -
$15.17
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$14.33
Resistance Level
$16.26
Current Trend
Downtrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
27.89
Wall Street Target
$17.50
(+16.2%)
Revenue Growth (YoY)
34.6%
Earnings Growth (YoY)
200.0%
Profit Margin
15.6%
Valuation Discount vs History
-18.2% cheaper
PE vs Historical
27.9 vs 50.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-18.2%
(market-implied from PE analysis)
1-Year Target
$13.55
(-10%)
2-Year Target
$12.20
(-19%)
3-Year Target
$10.98
(-27%)
3-Yr Target (if PE normalizes)
(PE: 28→51)
$20.04
(+33%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 27.9, Growth: 63.6%)
$50.83
(+238%)
Base:
(SPY PE: 21.8, Growth: 63.6%)
$39.69
(+164%)
Bear:
(PE: 18.5, Growth: 63.6%)
$33.74
(+124%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (36x PE), but valuation improves significantly next year (28x PE) as earnings recover.
Forward PE: 35.84 | Forward EPS (Implied): $0.42
Bull Case
$18.18
(+21%)
Analyst growth 15.0%, PE expands to 37.6
Base Case
$15.06
(0%)
Market implied 0.0%, PE stable at 35.8
Bear Case
$11.52
(-24%)
Severe decline -15.0%, PE contracts to 32.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 27.9 to 50.9
Stabilization Target:
$27.49
(+82.5%)
PE Expansion Potential:
+82.5%
Share & Embed Analysis
Last updated: July 13, 2026 12:43 PM ET
Data refreshes hourly during market hours. Next update: 1:43 PM
Data refreshes hourly during market hours. Next update: 1:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BWAY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$74 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 58 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$386 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$239 | 58 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$98 | 64 BUY |
